Header Logo

MICHAEL R MIGDEN

TitleAssociate Professor
InstitutionMD Anderson
DepartmentDermatology
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, Grob JJ, Lewis KD, Ansstas G, Day F, Ladwa R, Stein BN, Mu?oz Couselo E, Meier F, Hauschild A, Schadendorf D, Basset-Seguin N, Modi B, Dalac-Rat S, Dunn LA, Flatz L, Mortier L, Gu?gan S, Heinzerling LM, Mehnert JM, Trabelsi S, Soria-Rivas A, Stratigos AJ, Ulrich C, Wong DJ, Beylot-Barry M, Bossi P, Bug?s S?nchez C, Chandra S, Robert C, Russell JS, Silk AW, Booth J, Yoo SY, Seebach F, Lowy I, Fury MG, Rischin D. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6. J Am Acad Dermatol. 2024 Sep 07. PMID: 39245360.
      Citations:    Fields:    
    2. Gaudy-Marqueste C, Grob JJ, Garbe C, Ascierto PA, Arron S, Basset-Seguin N, Bohne AS, Lenoir C, Dummer R, Fargnoli MC, Guminski A, Hauschild A, Kaufmann R, Lallas A, Del Marmol V, Migden M, Penicaud M, Rembielak A, Stratigos A, Tagliaferri L, Zalaudek I, Arance A, Badinand D, Bossi P, Challapalli A, Clementi M, Di Stefani A, Ferr?ndiz-Pulido C, Giuffrida R, Gravina GL, Ha P, Heinzerling L, Mallet S, Paradisi A, Mohr P, Piccerillo A, Rutkowski D, Saiag P, Sollena P, Trakatelli M, Wojcieszek P, Yom SS, Zelin E, Peris K, Malvehy J. Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by experts. J Eur Acad Dermatol Venereol. 2024 Jul 03. PMID: 38961704.
      Citations:    Fields:    
    3. Stull CM, Clark D, Parker T, Idriss MH, Patel VA, Migden MR. Current and emerging intralesional immunotherapies in cutaneous oncology. J Am Acad Dermatol. 2024 Nov; 91(5):910-921. PMID: 38942173.
      Citations:    Fields:    Translation:Humans
    4. Idriss MH, Stull CM, Migden MR. Treatments on the horizon for locally advanced basal cell carcinoma. Cancer Lett. 2024 May 01; 589:216821. PMID: 38521198.
      Citations:    Fields:    Translation:Humans
    5. Rischin D, Hughes BGM, Basset-S?guin N, Schadendorf D, Bowyer S, Trabelsi Messai S, Meier F, Eigentler TK, Casado Echarren V, Stein B, Beylot-Barry M, Dalac S, Dr?no B, Migden MR, Schmults CD, Lim AM, Yoo SY, Paccaly AJ, Papachristos A, Nguyen JH, Okoye E, Seebach F, Booth J, Lowy I, Fury MG, Guminski A, Hauschild A. High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma. J Immunother Cancer. 2024 03 11; 12(3). PMID: 38471711; PMCID: PMC10936461.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    6. Lewis KD, Peris K, Sekulic A, Stratigos AJ, Dunn L, Eroglu Z, Chang ALS, Migden MR, Yoo SY, Mohan K, Coates E, Okoye E, Bowler T, Baurain JF, Bechter O, Hauschild A, Butler MO, Hernandez-Aya L, Licitra L, Neves RI, Ruiz ES, Seebach F, Lowy I, Goncalves P, Fury MG. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. Ann Oncol. 2024 Feb; 35(2):221-228. PMID: 38072158.
      Citations:    
    7. Stratigos AJ, Bechter O, Prey S, Basset-Seguin N, Dalle S, Licitra L, Robert C, Hauschild A, Dummer R, Loquai C, De Giorgi V, Gutzmer R, Ulrich J, Puig S, Sekulic A, Peris K, Lewis KD, Chang ALS, Fern?ndez Orland A, Ulrich C, Migden MR, Yoo SY, Okoye E, Bassukas I, Eroglu Z, Inocencio TJ, Chen CI, LaFontaine PR, Seebach F, Lowy I, Fury MG. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up. J Am Acad Dermatol. 2024 Feb; 90(2):414-418. PMID: 37839734.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    8. Baruch EN, Nagarajan P, Gleber-Netto FO, Rao X, Xie T, Akhter S, Adewale A, Shajedul I, Mattson BJ, Ferrarotto R, Wong MK, Davies MA, Jindal S, Basu S, Harwood C, Leigh I, Ajami N, Futreal A, Castillo M, Gunaratne P, Goepfert RP, Khushalani N, Wang J, Watowich S, Calin GA, Migden MR, Vermeer P, D'Silva N, Yaniv D, Burks JK, Gomez J, Dougherty PM, Tsai KY, Allison JP, Sharma P, Wargo J, Myers JN, Gross ND, Amit M. Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockade. Res Sq. 2023 Jul 18. PMID: 37503252; PMCID: PMC10371163.
      Citations:    
    9. Stafford H, Buell J, Chiang E, Ramesh U, Migden M, Nagarajan P, Amit M, Yaniv D. Non-Melanoma Skin Cancer Detection in the Age of Advanced Technology: A Review. Cancers (Basel). 2023 Jun 07; 15(12). PMID: 37370703; PMCID: PMC10295857.
      Citations:    
    10. Chen HY, Zhao W, Na'ara S, Gleber-Netto FO, Xie T, Ali S, Thompson ZM, Buell J, Stafford H, Nagarajan P, Davies M, Wong MK, Migden MR, Sharma P, Myers JN, Gross ND, Amit M. Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck Cancer. JCO Precis Oncol. 2023 06; 7:e2200490. PMID: 37285560; PMCID: PMC10309540.
      Citations:    Fields:    Translation:Humans
    11. Lear JT, Robert C, Grob JJ, Dummer R, Guminski A, Squittieri N, Migden M. Concomitant medication use does not appear to alter long-term efficacy of sonidegib for advanced basal cell carcinoma: a post hoc analysis based on the 42-month BOLT study. Eur J Dermatol. 2023 Jun 01; 33(3):280-286. PMID: 37594336.
      Citations:    Fields:    Translation:Humans
    12. Chiang E, Stafford H, Buell J, Ramesh U, Amit M, Nagarajan P, Migden M, Yaniv D. Review of the Tumor Microenvironment in Basal and Squamous Cell Carcinoma. Cancers (Basel). 2023 Apr 25; 15(9). PMID: 37173918; PMCID: PMC10177565.
      Citations: 1     
    13. Wilmas KM, Patel J, Silapunt S, Doan HQ, Migden MR. The Use of a Dehydrated Complete Human Placental Membrane Allograft for Mohs Surgical Defects of the Nose. Dermatol Surg. 2023 04 01; 49(4):343-347. PMID: 36799879.
      Citations:    Fields:    Translation:Humans
    14. Aboul-Fettouh N, Kubicki SL, Chen L, Silapunt S, Migden MR. Targeted Therapy and Immunotherapy in Nonmelanoma Skin Cancer. Dermatol Clin. 2023 Jan; 41(1):23-37. PMID: 36410980.
      Citations:    Fields:    Translation:Humans
    15. Migden M, Loquai C, Robert C, Baurain JF, Squittieri N, Arntz R, Dierlamm J, Dr?no B. Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73?weeks. JAAD Int. 2023 Mar; 10:31-33. PMID: 36425794; PMCID: PMC9678756.
      Citations:    
    16. Baig IT, Nguyen QD, Jahan-Tigh RR, Migden MR. Digital photography for the dermatologist. Clin Dermatol. 2023 Jan-Feb; 41(1):171-177. PMID: 36252727.
      Citations:    Fields:    Translation:Humans
    17. Chen OM, Kim K, Steele C, Wilmas KM, Aboul-Fettouh N, Burns C, Doan HQ, Silapunt S, Migden MR. Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma. Cancers (Basel). 2022 Jul 30; 14(15). PMID: 35954384; PMCID: PMC9367462.
      Citations:    
    18. Burns C, Kubicki S, Nguyen QB, Aboul-Fettouh N, Wilmas KM, Chen OM, Doan HQ, Silapunt S, Migden MR. Advances in Cutaneous Squamous Cell Carcinoma Management. Cancers (Basel). 2022 Jul 27; 14(15). PMID: 35954316; PMCID: PMC9367549.
      Citations:    
    19. Nguyen QB, Patel J, Migden M. Repair of an Extensive Defect of the Left Central Cheek. Dermatol Surg. 2023 01 01; 49(1):77-79. PMID: 35125443.
      Citations:    Fields:    
    20. Aboul-Fettouh N, Chen L, Silapunt S, Migden MR. Use of PD-1 Inhibitors in the Treatment of Advanced Basal Cell Carcinoma. Dermatol Surg. 2021 11 01; 47(11):1511-1512. PMID: 34699444.
      Citations:    Fields:    Translation:Humans
    21. Aboul-Fettouh N, Chen L, Ma J, Patel J, Silapunt S, Migden M. PD-1 inhibitors for cutaneous squamous cell carcinoma: A meta-analysis. Australas J Dermatol. 2022 Feb; 63(1):36-42. PMID: 34699068.
      Citations: 1     Fields:    Translation:Humans
    22. Lewis K, Farberg AS, Guminski A, Squittieri N, Migden M, Dummer R. Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial. Dermatol Ther (Heidelb). 2021 Dec; 11(6):2225-2234. PMID: 34669179; PMCID: PMC8611137.
      Citations: 3     
    23. Wilmas KM, Nguyen QB, Patel J, Silapunt S, Migden MR. Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective. Future Oncol. 2021 Dec; 17(35):4971-4982. PMID: 34608809.
      Citations:    Fields:    Translation:Humans
    24. Aboul-Fettouh N, Morse D, Patel J, Migden MR. Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma. Dermatol Pract Concept. 2021 Nov; 11(Suppl 2):e2021169S. PMID: 34877077; PMCID: PMC8609954.
      Citations: 1     
    25. Doan HQ, Chen L, Nawas Z, Lee HH, Silapunt S, Migden M. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma. Oncotarget. 2021 Sep 28; 12(20):2089-2100. PMID: 34611482; PMCID: PMC8487719.
      Citations: 2     Fields:    
    26. Aboul-Fettouh N, Patel J, Migden MR. Do Not Mess With Tattoos? Mohs Micrographic Surgery for Basal Cell Carcinoma Within the State of Texas. Dermatol Surg. 2021 09 01; 47(9):1273-1275. PMID: 34448763.
      Citations:    Fields:    Translation:Humans
    27. Rabinowits G, Migden MR, Schlesinger TE, Ferris RL, Freeman M, Guild V, Koyfman S, Pavlick AC, Swanson N, Wolf GT, Dinehart SM. Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma. JID Innov. 2021 Dec; 1(4):100045. PMID: 34909742; PMCID: PMC8659794.
      Citations:    
    28. Amit M, Liu C, Mansour J, Gleber-Netto FO, Tam S, Baruch EN, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Tsai K, Flores ER, Migden MR, Silverman DA, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer. 2021 12 01; 127(23):4413-4420. PMID: 34358340; PMCID: PMC10187975.
      Citations:    Fields:    Translation:Humans
    29. Rischin D, Khushalani NI, Schmults CD, Guminski A, Chang ALS, Lewis KD, Lim AM, Hernandez-Aya L, Hughes BGM, Schadendorf D, Hauschild A, Thai AA, Stankevich E, Booth J, Yoo SY, Li S, Chen Z, Okoye E, Chen CI, Mastey V, Sasane M, Lowy I, Fury MG, Migden MR. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer. 2021 08; 9(8). PMID: 34413166; PMCID: PMC8382148.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    30. Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Yoo SY, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG, Dalle S, Bassukas ID, Puig S. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):848-857. PMID: 34000246.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    31. Paccaly AJ, Migden MR, Papadopoulos KP, Yang F, Davis JD, Rippley RK, Lowy I, Fury MG, Stankevich E, Rischin D. Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis. Adv Ther. 2021 05; 38(5):2365-2378. PMID: 33768419; PMCID: PMC8107152.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    32. Sundaresan S, Migden MR, Silapunt S. Exercise-Induced Vasculitis in a Patient With Negative Ultrasound Venous Reflux Study: A Mimic of Stasis Dermatitis. Cutis. 2021 Feb; 107(2):E10-E11. PMID: 33891846.
      Citations:    Fields:    Translation:Humans
    33. Migden M, Farberg AS, Dummer R, Squittieri N, Hanke CW. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma. J Drugs Dermatol. 2021 02 01; 20(2):156-165. PMID: 33538567.
      Citations: 8     Fields:    Translation:HumansCells
    34. Lear JT, Guminski A, Leow LJ, Squittieri N, Migden M, Dummer R. Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42?months. J Am Acad Dermatol. 2021 Apr; 84(4):1162-1164. PMID: 33358380.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    35. Amit M, Liu C, Netto Gleber FO, Kini S, Tam S, Benov A, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Migden MR, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer. 2021 02; 144:169-177. PMID: 33352413.
      Citations:    Fields:    Translation:Humans
    36. Amit M, Liu C, Gleber-Netto FO, Kini S, Tam S, Benov A, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Migden MR, Baruch EN, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer. 2021 04 15; 127(8):1238-1245. PMID: 33320343.
      Citations: 2     Fields:    Translation:Humans
    37. Aria AB, Rosenbaum LE, Migden MR. Multiple inguinal basal cell carcinomas in the setting of intertrigo. Indian J Dermatol Venereol Leprol. 2020 Jul-Aug; 86(4):469. PMID: 31710000.
      Citations:    Fields:    Translation:Humans
    38. Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, Schadendorf D, Dunn LA, Hernandez-Aya L, Chang ALS, Modi B, Hauschild A, Stein B, Pavlick AC, Geiger JL, Gutzmer R, Alam M, Okoye E, Mathias M, Jankovic V, Stankevich E, Booth J, Li S, Lowy I, Fury MG, Guminski A, Ulrich C, Eigentler T. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020 06; 8(1). PMID: 32554615; PMCID: PMC7304829.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    39. Tam S, Yao CMKL, Amit M, Gajera M, Luo X, Treistman R, Khanna A, Aashiq M, Nagarajan P, Bell D, El-Naggar A, Migden M, Wong M, Glisson B, Ferrarotto R, Esmaeli B, Rosenthal D, Li G, Weber RS, Myers JN, Gross ND. Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. 2020 02 01; 146(2):128-135. PMID: 31804658; PMCID: PMC6902183.
      Citations: 5     Fields:    Translation:Humans
    40. Migden MR, Chandra S, Rabinowits G, Chen CI, Desai J, Seluzhytsky A, Sasane M, Campanelli B, Chen Z, Freeman ML, Ibrahim SF, Khushalani NI, Andria M, Ruiz E. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma. Future Oncol. 2020 Feb; 16(4):11-19. PMID: 31951149.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    41. Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, Meier F, Schadendorf D, Guminski A, Hauschild A, Wong DJ, Daniels GA, Berking C, Jankovic V, Stankevich E, Booth J, Li S, Weinreich DM, Yancopoulos GD, Lowy I, Fury MG, Rischin D. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020 02; 21(2):294-305. PMID: 31952975; PMCID: PMC7771329.
      Citations: 70     Fields:    Translation:HumansCTClinical Trials
    42. Dummer R, Guminksi A, Gutzmer R, Lear JT, Lewis KD, Chang ALS, Combemale P, Dirix L, Kaatz M, Kudchadkar R, Loquai C, Plummer R, Schulze HJ, Stratigos AJ, Trefzer U, Squittieri N, Migden MR. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020 06; 182(6):1369-1378. PMID: 31545507; PMCID: PMC7318253.
      Citations:    
    43. Ahmed SR, Petersen E, Patel R, Migden MR. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Expert Rev Clin Pharmacol. 2019 Oct; 12(10):947-951. PMID: 31524530.
      Citations: 19     Fields:    Translation:Humans
    44. Phadnis SS, Chen L, Wang WL, Migden MR, Zaky W. Disseminated anaplastic pleomorphic xanthoastrocytoma with posttreatment fat necrosis during combined BRAF and MEK inhibitors therapy. Pediatr Blood Cancer. 2019 12; 66(12):e27974. PMID: 31502413.
      Citations:    Fields:    Translation:Humans
    45. Silapunt S, Agwu AV, Migden MR. Severe pretibial myxedema refractory to systemic immunosuppressants. Cutis. 2019 Sep; 104(3):E1-E3. PMID: 31675401.
      Citations:    Fields:    Translation:Humans
    46. Chen L, Silapunt S, Petersen ET, Ahmed SR, Migden MR. Review of systemic agents in the treatment of advanced cutaneous squamous cell carcinoma. Future Oncol. 2019 Sep; 15(27):3171-3184. PMID: 31382778.
      Citations: 2     Fields:    Translation:HumansAnimals
    47. Sekulic A, Migden MR, Lao CD, Miller C, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, ERIVANCE BCC Investigators, Basset-Seguin N, Garbe C, Gesierich A, Mortier L, Schadendorf D, Hauschild A. Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2019 04 18; 19(1):366. PMID: 30999949; PMCID: PMC6474043.
      Citations: 3     Fields:    
    48. Sundaresan S, Migden MR, Silapunt S. Treatment of Leg Veins for Restless Leg Syndrome: A Retrospective Review. Cureus. 2019 Apr 02; 11(4):e4368. PMID: 31192073; PMCID: PMC6551200.
      Citations: 2     
    49. Chen L, Aria AB, Silapunt S, Migden MR. Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer. Dermatol Surg. 2019 01; 45(1):1-16. PMID: 30045105.
      Citations: 4     Fields:    Translation:Humans
    50. Fedda F, Migden MR, Curry JL, Torres-Cabala CA, Tetzlaff MT, Aung PP, Prieto VG, Ivan D, Myers JN, Nagarajan P. Angiotropism in recurrent cutaneous squamous cell carcinoma: Implications for regional tumor recurrence and extravascular migratory spread. J Cutan Pathol. 2019 Feb; 46(2):152-158. PMID: 30414196.
      Citations: 1     Fields:    Translation:Humans
    51. Aria A, Chen L, Rosenbaum LE, Migden MR. Mohs Micrographic Surgery for the Treatment of Cutaneous Metastases in a Patient With Papillary Thyroid Carcinoma. Dermatol Surg. 2018 11; 44(11):1457-1459. PMID: 29293107.
      Citations: 1     Fields:    Translation:Humans
    52. Yao C, Swaby MG, Migden MR, Silapunt S. A Nodular Hidradenoma of Atypical Location in Pregnancy. Acta Derm Venereol. 2018 Oct 10; 98(9):908-909. PMID: 29856466.
      Citations: 1     Fields:    Translation:Humans
    53. Rosenbaum LE, Migden MR. A Tender Subcutaneous Fluctuant Forehead Nodule: An Unexpected Foray Into the Cranium. Dermatol Surg. 2018 Sep; 44(9):1224-1227. PMID: 29315144.
      Citations:    Fields:    Translation:Humans
    54. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 07 26; 379(4):341-351. PMID: 29863979.
      Citations: 316     Fields:    Translation:HumansCTClinical Trials
    55. Balasubramanyam S, Migden MR, Silapunt S. Venous Treatment of Lipodermatosclerosis to Improve Ambulatory Function. Dermatol Surg. 2018 May; 44(5):749-752. PMID: 28858931.
      Citations: 1     Fields:    Translation:Humans
    56. Chen L, Parsons AM, Aria AB, Ciurea AM, Patel AB, Chan C, Griffin JR, Nguyen TH, Migden MR. Surgical site identification with personal digital device: A prospective pilot study. J Am Acad Dermatol. 2018 Sep; 79(3):520-524. PMID: 29524583.
      Citations:    Fields:    Translation:Humans
    57. Freemyer BD, Migden MR, Silapunt S. Linear terra firma-forme dermatosis of the midline back. Cutis. 2018 Mar; 101(3):205-206. PMID: 29718014.
      Citations:    Fields:    Translation:Humans
    58. Bendell J, Andre V, Ho A, Kudchadkar R, Migden M, Infante J, Tiu RV, Pitou C, Tucker T, Brail L, Von Hoff D. Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Na?ve and Previously Treated Basal Cell Carcinoma. Clin Cancer Res. 2018 05 01; 24(9):2082-2091. PMID: 29483143; PMCID: PMC6422158.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    59. Li JY, Silapunt S, Migden MR, McGinness JL, Nguyen TH. Mohs Mapping Fidelity: Optimizing Orientation, Accuracy, and Tissue Identification in Mohs Surgery. Dermatol Surg. 2018 Jan; 44(1):1-9. PMID: 28654580.
      Citations: 1     Fields:    Translation:Humans
    60. English CA, Chen L, Migden MR. Traction haemostasis. Australas J Dermatol. 2018 May; 59(2):156-157. PMID: 29243226.
      Citations:    Fields:    Translation:Humans
    61. Migden MR, Chang ALS, Dirix L, Stratigos AJ, Lear JT. Emerging trends in the treatment of advanced basal cell carcinoma. Cancer Treat Rev. 2018 Mar; 64:1-10. PMID: 29407368.
      Citations: 14     Fields:    Translation:Humans
    62. Chen L, Aria AB, Silapunt S, Lee HH, Migden MR. Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial. Future Oncol. 2018 Mar; 14(6):515-525. PMID: 29119833.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    63. Lear JT, Migden MR, Lewis KD, Chang ALS, Guminski A, Gutzmer R, Dirix L, Combemale P, Stratigos A, Plummer R, Castro H, Yi T, Mone M, Zhou J, Trefzer U, Kaatz M, Loquai C, Kudchadkar R, Sellami D, Dummer R. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018 Mar; 32(3):372-381. PMID: 28846163; PMCID: PMC5873455.
      Citations:    
    64. Rosales Santillan M, ATajnert K, Swaby MG, Migden MR, Silapunt S. Multiple eccrine spiradenomas in a zosteriform pattern. Dermatol Online J. 2017 Aug 15; 23(8). PMID: 29469747.
      Citations:    Fields:    Translation:Humans
    65. Sundaresan S, Migden MR, Silapunt S. Stasis Dermatitis: Pathophysiology, Evaluation, and Management. Am J Clin Dermatol. 2017 Jun; 18(3):383-390. PMID: 28063094.
      Citations: 6     Fields:    Translation:Humans
    66. Sekulic A, Migden MR, Lao CD, Miller C, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, ERIVANCE BCC Investigators, Basset-Seguin N, Garbe C, Gesierich A, Mortier L, Schadendorf D, Hauschild A. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017 05 16; 17(1):332. PMID: 28511673; PMCID: PMC5433030.
      Citations: 87     Fields:    Translation:HumansCellsCTClinical Trials
    67. Migden M, Xie J, Wei J, Tang W, Herrera V, Palmer JB. Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014. J Am Acad Dermatol. 2017 Jul; 77(1):55-62.e3. PMID: 28392293.
      Citations: 2     Fields:    Translation:Humans
    68. Wu W, Chavez-Frazier A, Migden M, Nguyen T. The Buried Half Horizontal, Half Vertical Mattress Suture: A Novel Technique for Wound Edges of Unequal Lengths. Dermatol Surg. 2016 Dec; 42(12):1391-1393. PMID: 27427995.
      Citations: 2     Fields:    Translation:Humans
    69. Chang AL, Lewis KD, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A. Safety and efficacy of vismodegib in patients aged =65 years with advanced basal cell carcinoma. Oncotarget. 2016 11 15; 7(46):76118-76124. PMID: 27764798; PMCID: PMC5342800.
      Citations: 5     Fields:    Translation:HumansCells
    70. Migden M. Hedgehog pathway inhibitor therapy in basal-cell nevus syndrome. Lancet Oncol. 2016 12; 17(12):1631-1632. PMID: 27838223.
      Citations:    Fields:    Translation:Humans
    71. Doan HQ, Silapunt S, Migden MR. Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma. Onco Targets Ther. 2016; 9:5671-5678. PMID: 27695345; PMCID: PMC5028081.
      Citations: 9     
    72. Chang AL, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016 09 01; 11(1):120. PMID: 27581207; PMCID: PMC5007799.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    73. Chitsazzadeh V, Coarfa C, Drummond JA, Nguyen T, Joseph A, Chilukuri S, Charpiot E, Adelmann CH, Ching G, Nguyen TN, Nicholas C, Thomas VD, Migden M, MacFarlane D, Thompson E, Shen J, Takata Y, McNiece K, Polansky MA, Abbas HA, Rajapakshe K, Gower A, Spira A, Covington KR, Xiao W, Gunaratne P, Pickering C, Frederick M, Myers JN, Shen L, Yao H, Su X, Rapini RP, Wheeler DA, Hawk ET, Flores ER, Tsai KY. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun. 2016 08 30; 7:12601. PMID: 27574101; PMCID: PMC5013636.
      Citations: 50     Fields:    Translation:HumansAnimals
    74. Silapunt S, Chen L, Migden MR. Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness. Ther Adv Med Oncol. 2016 Sep; 8(5):375-82. PMID: 27583029; PMCID: PMC4981290.
      Citations: 8     
    75. Chen L, Silapunt S, Migden MR. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update. Future Oncol. 2016 Sep; 12(18):2095-105. PMID: 27189494.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    76. Guminski A, Gutzmer R, Dirix L, Lewis KD, Herd RM, Kaatz M, Loquai C, Stratigos AJ, Plummer R, Gogov S, Pallaud C, Yi T, Mone M, Chang AL, Kudchadkar R, Trefzer U, Lear JT, Sellami D, Migden MR, Dummer R, Combemale P, Schulze HJ, Corn?lis F. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016 Jul; 75(1):113-125.e5. PMID: 27067394.
      Citations: 49     Fields:    Translation:HumansCTClinical Trials
    77. Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Dirix L, Hou J, Yue H, ERIVANCE BCC investigators, Hauschild A. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015 Jun; 72(6):1021-6.e8. PMID: 25981002.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    78. Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Plummer R, Chang AL, Lear JT, Sellami D, Schulze HJ, Corn?lis F, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun; 16(6):716-28. PMID: 25981810.
      Citations: 120     Fields:    Translation:HumansCTClinical Trials
    79. Ozgur OK, Yin V, Chou E, Ball S, Kies M, William WN, Migden M, Thuro BA, Esmaeli B. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Am J Ophthalmol. 2015 Aug; 160(2):220-227.e2. PMID: 25935097.
      Citations: 7     Fields:    Translation:Humans
    80. Sharpe HJ, Pau G, Dijkgraaf GJ, Modrusan Z, Januario T, Tsui V, Durham AB, Dlugosz AA, Haverty PM, Bourgon R, Tang JY, Sarin KY, Dirix L, Fisher DC, Rudin CM, Sofen H, Migden MR, Yauch RL, de Sauvage FJ, Basset-Seguin N. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015 Mar 09; 27(3):327-41. PMID: 25759019; PMCID: PMC5675004.
      Citations: 148     Fields:    Translation:HumansCells
    81. Lim L, Nichols B, Migden MR, Rajaram N, Reichenberg JS, Markey MK, Ross MI, Tunnell JW. Clinical study of noninvasive in vivo melanoma and nonmelanoma skin cancers using multimodal spectral diagnosis. J Biomed Opt. 2014; 19(11):117003. PMID: 25375350; PMCID: PMC4222134.
      Citations: 27     Fields:    Translation:Humans
    82. Anzalone CL, Cohen PR, Migden MR, Tannir NM. Mohs surgery in metastatic cancer: renal cell carcinoma solitary cutaneous metastasis and visceral tumor metastases to skin treated with microscopically controlled surgical excision. Int J Dermatol. 2013 Jul; 52(7):856-61. PMID: 23675612.
      Citations: 2     Fields:    Translation:Humans
    83. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 07; 366(23):2171-9. PMID: 22670903; PMCID: PMC5278761.
      Citations: 415     Fields:    Translation:HumansCellsCTClinical Trials
    84. Rajaram N, Reichenberg JS, Migden MR, Nguyen TH, Tunnell JW. Pilot clinical study for quantitative spectral diagnosis of non-melanoma skin cancer. Lasers Surg Med. 2010 Dec; 42(10):716-27. PMID: 21246575; PMCID: PMC3059518.
      Citations: 36     Fields:    Translation:Humans
    85. Migden M, Chavez-Frazier A, Nguyen T. The use of high definition video modules for delivery of informed consent and wound care education in the Mohs Surgery Unit. Semin Cutan Med Surg. 2008 Mar; 27(1):89-93. PMID: 18486030.
      Citations: 10     Fields:    Translation:Humans
    86. Cowl CT, Prakash UB, Shawn Mitchell P, Migden MR. Varicella-zoster virus detection by polymerase chain reaction using bronchoalveolar lavage specimens. Am J Respir Crit Care Med. 2000 Aug; 162(2 Pt 1):753-4. PMID: 10934116.
      Citations: 5     Fields:    Translation:HumansCells
    87. Migden MR, Dennis WH, Clinch TE. Testing for hepatitis B surface antigen in processing donor tissue for penetrating keratoplasty. Am J Ophthalmol. 1996 Sep; 122(3):439-42. PMID: 8794725.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    88. Migden M, Elkins BS, Clinch TE. Phototherapeutic keratectomy for corneal scars. Ophthalmic Surg Lasers. 1996 May; 27(5 Suppl):S503-7. PMID: 8724160.
      Citations: 6     Fields:    Translation:Humans
    89. Sonidegib for the treatment of advanced basal cell carcinoma. Future Oncology. 12:2095-2105.
    90. Reconstruction of the Ears. 135-145.
    91. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nature Communications. 7.
    92. Hedgehog pathway inhibitor therapy in basal-cell nevus syndrome. The Lancet Oncology. 17:1631-1632.
    93. Mohs' micrographic surgery of the periorbital area. 571-587.
    94. Hedgehog pathway inhibition in advanced basal cell carcinoma. Therapeutic Advances in Medical Oncology. 8:375-382.
    95. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT). Journal of the American Academy of Dermatology.
    96. Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma. OncoTargets and Therapy. 9:5671-5678.
    97. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome. Orphanet Journal of Rare Diseases. 11.
    98. The Buried Half Horizontal, Half Vertical Mattress Suture. Dermatologic Surgery. 42:1391-1393.
    99. In vivo determination of optical properties and fluorophore characteristics of non-melanoma skin cancer.
    100. Oncotarget. 7:76118-76124.
    MIGDEN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (253)
    Explore
    _
    Co-Authors (40)
    Explore
    _
    Similar People (59)
    Explore
    _
    Same Department Expand Description
    Explore
    _